Virtual events · All times US Eastern
23rd Annual · April 2025 · Virtual

2025

  • 29 faculty
  • 6 recordings
  • 9:00 AM
    Introductory Notes on the 23nd Annual MCI Symposium
    Ranjan Duara, MD, FAANMt Sinai Medical Center/Wien Center for Alzheimer's Disease and Memory Disorders
9:15 AM - 11:30 PM
Session 1

SUCCESSFUL AGING OF THE BRAIN

Chair: Judy Pa, PhDUCSD

12:00 PM - 2:20 PM
Session 2

WHITE MATTER DISEASE OF THE BRAIN

Chair: Adam Brickman, PhDColumbia University

  • 12:00
    Session Overview
  • 12:05
    Keynote Etiology of White Matter Disease in Autosomal Dominant and Sporadic Alzheimer’s Disease in the DIAN Study
    Jasmeer Chhatwal, MD, PhDHarvard/MGH
  • 12:35
    White Matter Abnormalities in Autosomal Dominant Alzheimer's Disease: Findings from the Colombia-Boston (COLBOS) Biomarker Study
    Yakeel Quiroz, PhDHarvard/MGH
  • 12:55
    Remembering Dr. Francisco Lopera
    Mónica Rosselli, PhDFlorida Atlantic University
    Yakeel Quiroz, PhDHarvard/MGH
  • 1:00
    White Matter Hyperintensities: Can They Be Treated?
    Christopher Filley, MDUniversity of Colorado School of Medicine
  • 1:20
    Cerebral Small Vessel Disease–Related Dementia: More Questions Than Answers
    Fanny Elahi, MD, PhDIcahn School of Medicine at Mount Sinai
  • 1:40
    Genetic Predisposition for White Matter Hyperintensities and Risk of Mild Cognitive Impairment and Alzheimer’s Disease: Results from the HELIAD Study
    Nikolaos Scarmeas, MD, MSColumbia University
  • 2:00
    Discussion
2:20 PM - 4:40 PM
Session 3

UPDATE ON ANTI-AMYLOID TREATMENTS

Chair: Ronald Petersen, MD, PhDMayo Clinic, Rochester

9:40 - 11:20
Session 1

SCREENING AND DIAGNOSIS OF ALZHEIMER'S DISEASE

Chair: Mary Ganguli, MD, MPHUniversity of Pittsburgh

11:20 - 12:40
Session 2

OPTIMIZING SUCCESSFUL AGING

Chair: Glenn Smith, PhD, ABPPUniversity of Florida

12:40 - 1:40
Session 3

NEW PHARMACOLOGICAL TREATMENTS FOR ALZHEIMER'S DISEASE

Chair: Steven DeKosky, MDUniversity of Florida

  • 12:40
    Session Overview
  • 12:45
    Developments in Anti-amyloid Treatments and Progress with Anti-Tau, GLP1 RA ( “Ozempic”, etc) and Other Agents
    Jeffrey Cummings, MD, ScDUniversity of Nevada, Las Vegas
  • 1:10
    DISCUSSION
  • 1:30
    Concluding Remarks
    Ranjan Duara, MD, FAANMount Sinai Medical Center
  • 1:35
    End

Programs, recordings and slides as published at the time. Slides and recordings appear only where speakers chose to share them. Affiliations are as of 2025.